TB

This is a flipbook from the Multnomah Health Department for patients with tuberculosis (TB) disease. The flipbook has information on TB disease, testing, case management, treatment, and more.

This information sheet discusses multidrug-resistant TB (MDR TB), a strain of TB that is resistant to at least two of the best anti-TB drugs, isoniazid and rifampicin. It describes TB disease, MDR TB, extensively drug resistant TB (XDR TB), TB transmission, how drug resistance happens, and who is at risk for getting MDR TB. The information sheet also explains how MDR TB can be prevented, TB vaccine, the symptoms of TB disease, and what an individual should do after being exposed to someone with TB.

This information sheet discusses the treatment of TB disease in individuals who are not infected with HIV and who are not resistant to any of the drugs used to treat TB disease. It follows the guidelines released in 2003 by the American Thoracic Society, CDC, and the Infectious Diseases Society of America. It describes the recommended regimens for treating TB using the first line anti-TB drugs isoniazid, rifampin, ethambutol, and pyrazinamide, and explains the initial and continuation phases of treatment.

This information sheet discusses TB and how it is affected by HIV. It defines TB and explains the difference between TB infection and TB disease. The information sheet advises that HIV weakens the immune system, increasing the chance that in people with HIV and latent TB, the TB germs will become active and attack the body, causing TB disease. It emphasizes the importance of TB treatment and taking the TB drugs as prescribed.

This information sheet discusses TB testing and treatment for pregnant women. It explains that tuberculin skin testing is safe during pregnancy, and describes the treatment regimen for pregnant women with latent TB infection (LTBI) or TB disease. It also describes the treatment regimen for HIV-infected women suspected of being coinfected with TB.

This information sheet discusses TB in Hispanics/Latinos. It explains TB disease the incidence of TB disease in Hispanics/Latinos for 2011 including the reported TB cases by origin and race/ethnicity in the United States 2011. The information sheet explains challenges faced in preventing TB including socioeconomic factors, language and cultural barriers, stigma associated with the disease and other underlying medical conditions that may increase the risk of latent TB becoming active disease. It describes what CDC is doing to achieve TB elimination.

This document is intended for use as a reference manual for clinicians caring for persons with or at high risk for TB disease or infection. It is not meant to provide detailed answers to all public health or clinical questions about TB, and it is not meant as a substitute for any specific guidelines.

This information sheet discusses the once-a-week 12-week treatment of rifapentine and isoniazid for latent TB infection (LTBI). It explains LTBI, why it is necessary to treat it, the treatment plan and how it is managed, and a chart for tracking. It also includes hints on how to take the medicine including eating before taking it and avoiding alcohol, and describes normal side effects and possible problems including which signs and symptoms require you to call the doctor or nurse and what to do when taking a dose of medicine in the absence of medical staff.

This video was created by the WHO Global TB Programme for World TB Day 2019. This short video encourages viewers to participate in ending TB through testing, treatment, and information sharing.

This information sheet discusses how CDC is working to prevent extensively drug-resistant TB (XDR TB).